05/2021: Tcell Tolerance GmbH assigned UGA Biopharma to develop a highly efficient CHO cell line and bioprocess
Biopharma is developing a new and more efficient CHO-DG44 cell line for
German-based startup Tcell Tolerance GmbH to express its Palixizumab® antibody.
cell line will assist Tcell Tolerance in its quest to develop an innovative
therapy to prevent graft-versus-host disease (GvHD), which occurs after
allogeneic hematopoietic stem-cell transplantation (HSCT). Tcell Tolerance
wants to develop a safer HSCT therapy that can be translated into clinical
To read the
full article, please click here.